NCT03309878 2023-09-21Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaNational Cancer Institute (NCI)Phase 1/2 Completed8 enrolled 10 charts